SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2067 participants.
Also called NCT03982381
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 2,067 participants
- Registry
-
NCT03982381 -
2019-001046-17
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Sweden
- Registry status
- Completed
Technical summary
Registry record NCT03982381. Randomized; single masking; primary purpose treatment. Start 2019-09-05 (actual); primary completion 2026-01-31 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- SGLT2 Inhibitor or Metformin as Standard Treatment of Early Stage Type 2 Diabetes
- Acronym
- SMARTEST
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Dapagliflozin 10 MG
- Lead sponsor
- Uppsala University
- Collaborator
- Uppsala University Hospital
- Collaborator
- Swedish Healthcare Regions
- Collaborator
- National Board of Health and Welfare, Sweden
- Collaborator
- The Swedish National Diabetes Register
Record details
- Record id
cardio:ct-nct03982381- Content hash
082c05de619f82b1b5e3e274c0d7d4d3092eb3d5789a5ba74f2456e4cd857830